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by counterflow centrifugation. Eighteen patients died 
within 3 months after bone marrow transplantation  
without evidence of CMV infection, and they were ex ­
cluded from analysis. Tw enty-eight valuable seronega­
tive patients received marrow from a seronegative, do­
nor, and 13 from a seropositive donor. All but 2 patients 
received acyclovir orally (4 x 4 0 0  mg/day) from days —9 
to + 60. CMV prophylaxis with immunoglobulin prepa­
rations was not given. All blood products were prepared 
from random, CMV-unscreened blood-bank donors. The 
red cell concentrates were depleted of leukocytes by 
filtration, and leukocytes were removed from the plate­
let concentrates by centrifugation. None of the patients
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with seronegative donors showed any clinical sign com­
patible with CMV infection. Two nonfatal primary CMV 
infections occurred in the recipients of bone marrow  
from CMV-positive donors. One of the 59 patients de­
veloped interstitial pneumonia, in this case caused by 
P n e u m o c y s t i s  c a r i n i i .
Leukocyte depletion of blood products from random 
CMV-unselected blood donors appeared to prevent pri­
mary infection in CM V-seronegative BMT recipients. 
We conclude that prophylactic use of immunoglobulin 
preparations is not necessary to prevent CMV primo- 
infection in patients receiving leukocyte-depleted blood 
products and acyclovir prophylaxis during the first 2 
months postgrafting.
C ytom egalov irus  in fec tion  is th e  m o s t  co m m o n  in fec tious  
cause of d e a th  a f te r  bone  m arro w  t r a n s p la n ta t io n  (7). C M V  
infection  a f te r  B M T  has  been  re p o r te d  to  occur in 31 -80%  of 
th e  rec ip ien ts  (1-3) .  C M V  in fec tion  m ay  arise  from  reac t iv a t io n  
of a la te n t  en d o g en o u s  v irus, from  d o n o r  b one  m arrow , blood 
p roduc ts ,  or close physica l  c o n ta c ts  (4). In  C M V -seropos it ive  
rec ip ien ts , re a c t iv a t io n  of l a te n t  en d o g en o u s  v irus  is p ro b ab ly  
the  m o s t  f re q u e n t  source  of in fec tion , as m ay  be concluded  
from th e  high inc idence  of C M V  in fec tion  in rec ip ien ts  w ith  
positive C M V  serology p r io r  to  B M T , as co m p a red  to  th e  
relatively  low inc idence  o f  C M V  in fec tion  in C M V -se ro n eg a tiv e  
rec ip ien ts  (5, 6). T h e  inc idence  of p r im a ry  C M V  in fec tion  in 
seronegative  rec ip ien ts  ran g ed  from  24% to  42% in five recen t  
repo rts  {1, 7-10) .
Severa l a p p ro a c h e s  m ay  reduce th e  inc idence  o f  C M V  in fec ­
tion  in se ronega tive  rec ip ien ts .  S e ro n eg a tiv e  p a t ie n ts  receiv ing 
t r a n s p la n ts  from  se ronega tive  d o n o rs  were found  to  have  th e  
lowest risk  o f  C M V  in fec tion  (7), b u t  se ronega tive  d o n o rs  are 
no t read ily  available . T h e  use o f  b lood p ro d u c ts  from  se ro n eg ­
ative b lood d o n o rs  has  been  successfu lly  app lied  in B M T  w ith  
m arrow  from  se ronega tive  donors ,  w h ereas  no p ro te c t io n  was 
observed a m o n g  p a t ie n ts  receiv ing  se roposit ive  m arro w  (8, 9). 
Oral acyclovir given to  p re v e n t  h e rp es  in fec tio n s  m ay also 
provide p ro te c t io n  a g a in s t  C M V  in fec tion  {11, 12). Severa l 
s tudies  have suggested  t h a t  pass ive  im m u n iz a t io n  w ith  C M V  
h y p e r im m u n e  globulin  m ay  reduce  th e  severity  o f  C M V  in fec ­
tion a n d  th e  inc idence  o f  C M V  in te rs t i t ia l  p n e u m o n ia  (IP)* 
af te r  B M T  (10, 13). In  se ronega tive  rec ip ien ts ,  con flic t ing  d a ta  
have been  repo rted . In  one s tu d y  p ro p h y lac t ic  use o f  h y p e r im ­
m une globulin  did  n o t  reduce th e  inc idence  o f  C M V  infec tion  
(8), b u t  M eyers  e t  al. re p o r te d  com ple te  p re v e n t io n  in 11 
seronegative  rec ip ien ts  w ith  se ro n eg a t iv e -m arro w  d o n o rs  (10).  
Since th e  leukocy te  f rac t ion  o f  d o n o r  b lood has  been  im p lica ted  
as a source  o f  v irus  (14, 15), a p o te n t ia l  a l te rn a t iv e  is th e  use 
of leukocy te -poor b lood  p ro d u c ts .  W e p re se n te d  here  th e  8-year 
experience in a bone  m arro w  t r a n s p la n t  p ro g ram  w ith  a blood 
transfus ion  policy o f  leukocy te -poor  b lood p ro d u c ts  o b ta in e d  
from v o lu n tee r  b lood d o n o rs  n o t  se lec ted  for C M V -a n t ib o d y  
status.
M ATERIALS A N D  M ETH O D S
Patients. One hundred and twenty consecutive patients received a 
>one marrow graft from a sibling between May 1981 and March 1989. 
?ifty-nine bone marrow recipients were CMV seronegative and 61 
eropositive. Eighteen of the seronegative patients died within 3 months
* Abbreviations: AEU, arbitrary ELISA units, CML, chronic mye- 
ogenous leukemia; CMV-EA, cytomegalovirus-induced early antigen; 
'R, complete remission; IP, interstitial pneumonia; SAA, severe aplas- 
ic anemia.
after transplantation without evidence of CMV infection and were 
excluded from analysis. The remaining 41 patients with negative CMV  
serology formed the main group of this analysis. The median age of  
this group was 27 years (range: 13-44 years).
The indications for B M T  were: acute myeloid leukemia in 11 patients  
(10 in first complete remission [CR], 1 in partial remission); acute 
lymphocytic or undifferentiated leukemia or lymphoblastic lymphoma  
in 16 patients (12 in first CR, 4 in second CR); chronic myelogenous 
leukemia (CML) in 9 patients (6 in first chronic phase, 3 in accelerated 
phase); myelodysplastic syndromes in 4 patients; and severe aplastic 
anemia (SAA) in 1 patient.
Conditioning. The transport conditioning consisted of cyclophos­
phamide 60 mg/kg body weight (days - 6  and - 5 ) ,  and total-body 
irradiation in two equal fractions of 450 cGy each on 2 consecutive 
days (days —2 and —1) using an 18-mV photon-beam linear accelerator 
(Saturne, CGR, BUC, France) at a dose rate of 5.5 cGy/m in in 22 
patients and 22 cGy/m in in 16 patients. Lung and eye shielding was 
used on the second day of irradiation (16, 17). Anthracyclines to reduce 
leukemic relapse after transplantation were added to the conditioning  
regimen in 22 patients (18). The only patient with a mismatched family 
donor (1 mismatch at A-locus) received a total TBI dose of 12 Gy (two 
fractions of 6 Gy). One patient with SAA received total-lymphoid  
irradiation (six fractions with a total dose of 12 Gy). One patient who 
relapsed after B M T  was retransplanted with unmanipulated marrow 
from the same donor, and the conditioning regimen consisted of busul- 
phan (4 mg/kg body weight) orally for 4 days, followed by cyclophos­
phamide (50 mg/kg body weight) intravenously for 4 days.
D onor marrow. Donor marrow was depleted of 97-98% of lympho­
cytes by counterflow-centrifugal élutriation as described before (19). 
Bone marrow was infused 24 hr after completion of the total-body 
irradiation.
M anagem ent o f the patients. Details have been described in earlier 
reports (16, 17). Twelve patients received immunoprophylaxis consist­
ing of CsA followed by weekly injections of methotrexate; 2 patients 
received methotrexate alone, and 27 patients CsA alone. All patients 
except the first 2 patients in this analysis received acyclovir orally 
(4x400 mg/day) from days —9 to -1-60 for prophylaxis of herpes virus 
infections. Acyclovir was given intravenously (3x5 mg/kg/day) when 
oral intake was impaired. CMV prophylaxis with hyperimmune globulin 
was not given. All patients were managed in single rooms with filtered 
air under positive pressure throughout the transplant period, and all 
received selective gut decontamination including co-trimoxazole for 
P neum ocystis carinii prophylaxis.
Blood products. All cell-containing blood products were irradiated 
(20 Gy) and prepared from random blood donors (nonpaid volunteers, 
about 50% of them have positive CMV serology). Leukocytes were 
removed from fresh red-cell concentrates (within 36 hr after collection) 
immediately prior to use by fiber filtration (NPBI CellSelect filter). 
This resulted in a white cell count of < 5 x l0 7/L  in all instances, but 
most of the time the WCC was below the detection level of < 1X 107/L
(20). Platelet concentrates were usually prepared from 6 buffy coats 
(one “random” platelet concentrate =  6 units) and subsequently sub­
jected to an additional centrifugation step for removal of the leukocytes
(21). The number of nucleated cells per concentrate was less than 
1X108 in 93% of the 286 tested concentrates. In case of refractoriness 
to platelets from random blood donors, platelet concentrates were 
prepared from CMV-unscreened HLA-matched blood-bank donors or 
relatives of the patient using cell separators. The single-donor-platelet 
concentrates contained less than 1X108 nucleated cells in 75% of the 
60 tested concentrates. No granulocyte transfusions were given.
The general policy in our institution and in most referring hospitals 
was to give leukocyte-poor blood products to all B M T  candidates and 
to all marrow recipients.
C M V  m onitoring. IgG, IgA, and IgM antibodies to CMV were tested  
using enzyme-linked immunosorbent assays prior to B M T  in serum of  
both donor and recipient (22, 23). Reciprocal antibody levels of >10  
arbitrary ELISA units (AEU) were considered positive (22, 23). A 
serum titer rise of 4 times or higher was considered significant. Serology 
was performed once weekly until 16 weeks after B M T  and thereafter 3
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monthly until 12 months after transplantation. The presence of CMV  
in cultures was determined by indirect immunofluorescence using 
monoclonal antibodies against CMV-induced early antigen (CMV-EA). 
CMV-EA was determined in the urine of the recipient prior to BM T  
and weekly thereafter until 16 weeks postgrafting (24). When CMV-IP  
was suspected (vide infra) a bronchoalveolar lavage was always per­
formed, and the lavage material was cultured for the presence of CMV.
D efinitions. CMV infection was defined either as primary infection 
or as reactivation: (1) primary infection was defined as a seroconverison 
with antibody levels persistently above 10 AEU and/or positive cultures 
in a previously seronegative recipient; and (2) reactivation was defined 
as a rise in antibody level of at least fourfold and/or positive cultures 
in a previously seropositive patient.
CMV disease was defined as a clinical syndrome characterized by 
fever, leukocytopenia, hepatitis, interstitial pneumonia, or encephalitis 
associated with CMV-positive cultures obtained from the suspected 
sites.
CMV interstitial pneumonia was defined as a syndrome consisting  
of fever, tachypnea, hypoxia, chest X-ray compatible with IP, and 
demonstration of virus in bronchoalveolar lavage.
R E SU L T S
Seronega tive  m arrow  recipients. T w elve  of th e  41 evaluab le  
seronegative  p a t ie n ts  died la te r  th a n  3 m o n th s  a f te r  B M T . T e n  
p a t ie n ts  d ied due to recu rren ce  of th e  u n d e r ly in g  d isease  an d  2 
p a t ie n ts  due to  infections: genera lized  cand id ias is  in one p a t ie n t  
an d  in te rs t i t ia l  p n e u m o n ia  caused  by P n eu m o cystis  carin ii in 
th e  o ther .  T h e se  d iagnoses were co n f irm ed  a t  au to p sy  in b o th  
p a t ie n ts .  T h e  m ed ian  follow-up of th e  n o n su rv iv in g  p a t ie n ts  
was 253 days (range: 124-1179 days). M ed ian  follow-up o f  th e  
surv iv ing  p a t ie n ts  was 760 days (range: 330-2160  days).
C M V  s ta tu s  o f bone m arrow  donors a n d  C M V  infection. 
T w en ty -e ig h t  evaluab le  se ronega tive  p a t ie n ts  received m arrow  
from seronega tive  d o n o rs  an d  13 from  seroposit ive  donors . 
N o n e  of th e  28 C M V -sero n eg a tiv e  rec ip ien ts  w ith  a C M V  
seronegative  do n o r  show ed any  evidence of C M V  infection . 
T w o of th e  13 p a t ie n ts  w ith  seroposit ive  bone  m arro w  d o n o rs  
developed evidence of C M V  infection . O ne o f  th e m  serocon- 
ve r ted  6 w eeks a f te r  B M T  w ith  rap id ly  r is ing  IgG, IgM , an d  
IgA an tib o d y  t i te rs .  C M V  was excre ted  in th e  u r ine  for m ore 
th a n  6 m o n th s .  T h e  p a t ie n t  never developed  signs of C M V  
disease, an d  th e re fo re  specific a n t i -C M V  t r e a tm e n t  was not 
in s t i tu ted .  T h e  o th e r  p a t ie n t  developed  IgG an tib o d ie s  w ith  
c o n c o m ita n t  positive  u r in e  cu ltu res .  H e developed  fever, signs 
of g a s tro en te r i t is ,  a n d  m ild  m yelosuppress ion . T r e a tm e n t  w ith  
ganciclovir (5 m g /k g  i.v. 3 t im es  daily  for 7 days) (D H P G , 
S y n tex  M aid en h ead , U .K .), a n d  in t ra v e n o u s  h y p e r im m u n e  
globulin  (2 m l /k g  body w eight) (C y to tec t,  B io te s t  P h a rm a ,  
G M B H , F ra n k fu r t  am  M ain , F R G ) was im m ed ia te ly  in s t i tu te d  
an d  m ay  have c o n tr ib u te d  to  th e  rap id  re so lu tion  of all s y m p ­
tom s. T h re e  in fus ions  w ith  iden tica l dosages of h y p e r im m u n e  
globulin  were given d u r in g  6 ad d it io n a l  weeks. N o re lapse  of 
clinical d isease  was observed. N e i th e r  p a t ie n t  h ad  any  sy m p to m  
of acu te  n o r  ch ro n ic  g ra f t-v e rsu s -h o s t  disease. B o th  p a t ie n ts  
are  c u r re n t ly  alive a n d  in rem iss ion  m ore  th a n  3 a n d  2 years  
a f te r  B M T , respectively .
C M V  in fection  a n d  tra n sfu sed  blood products. Six p a t ie n ts  
w ith  C M L  received no blood p ro d u c ts  p r io r  to  B M T . T h e  
n u m b e r  of t r a n s fu se d  blood p ro d u c ts  p r io r  to  B M T  was u n ­
know n  for 6 p a t ie n ts .  T h e  re m a in in g  29 p a t ie n ts  received a 
m ed ian  n u m b e r  of 6 red-cell c o n c e n tra te s  (range: 0 -31  un its )  
in th e  3 m o n th s  p r io r  to  B M T . A m ed ian  n u m b e r  o f  30 u n i ts  
“r a n d o m ” p la te le ts  (range: 6 -1 0 8  u n its )  a n d  2 u n i ts  from  single 
d o n o rs  (range: 2 -1 0  u n its )  were given to  13 an d  6 p a t ie n ts ,
respectively , in th e  3 m o n th s  im m ed ia te ly  p r io r  to  B M T  (Table  
1). In th e  f irs t  3 m o n th s  a f te r  B M T , a m ed ian  n u m b e r  of 12 
red-cell u n i ts  was given (range: 6 -30); th e  m ed ian  n u m b e r  of 
u n i ts  o f “r a n d o m ” p la te le ts  (for 38 p a t ie n ts )  was 36 (range: 6 -  
222), a n d  a m ed ian  n u m b e r  of 4 u n i ts  (range: 1-10) from  single 
d o n o rs  was given to  16 p a t ie n ts .  O f th e  2 p a t ie n ts  w ith  CM V 
infec tion , one had  n o t  received an y  t ra n s fu s io n  p r io r  to  B M T , 
b u t  he received 16 u n i ts  of red-cell c o n c e n tra te s ,  a n d  30 un its  
of “r a n d o m ” p la te le ts  a f te r  B M T . T h e  o th e r  p a t i e n t  received 
16 u n i ts  o f  red cells p r io r  to  B M T  an d  16 u n i ts  a f te r  B M T . She 
also received 108 u n i ts  o f  “r a n d o m ” p la te le ts  an d  7 un its  
p re p a re d  from  single d o n o rs  in th e  p o s t t r a n s p la n t  period.
Seropositive  m arrow  recip ien ts and  C M V  infection. IgM  a n ­
tibodies, in d ica t in g  recen t or ac tive  C M V  infec tion , were d e te r ­
m ined  in 57 of th e  61 C M V -seropos it ive  rec ip ien ts  p r io r  to 
B M T . F o u r  of th e  57 ev a lu a ted  rec ip ien ts  had  positive  IgM 
an tibod ies .  T h re e  p a t ie n ts  had  received t r a n s fu s io n s  in o the r  
in s t i tu t io n s .  T h e  fo u r th  p a t ie n t  developed  C M V  in te rs t i t ia l  
p n e u m o n ia  a t p re s e n ta t io n  w ith  C M L  before an y  t ran s fu s io n  
was given. T h is  p a t ie n t  received a t r a n s p la n t  u n ev en tfu l ly  6 
m o n th s  a f te r  full recovery  from th e  p n e u m o n ia  th a t  had  re ­
qu ired  artif ic ia l v e n t i la t io n  for 2 weeks. N in e  p a t ie n ts  died 
w ith in  3 m o n th s  a f te r  B M T  w ith o u t  ev idence o f  C M V  infection. 
T h e  re m a in in g  48 p a t ie n ts  were ev a lu a ted  for C M V  infection. 
E leven  p a t ie n ts  received m arrow  from  a se ronega tive  donor. 
All developed  C M V  in fec tion  lead ing  to  fa tal C M V -IP  in 1 
p a t ie n t  an d  fa ta l C M V  ap las ia  in a n o th e r  p a t ie n t .  T h ir ty -se v e n  
p a t ie n ts  received m arro w  from  a seroposit ive  d o n o r  or a donor 
w ith  u n k n o w n  C M V  serology. C M V  in fec tion  was d e tec ted  in 
31 p a t ie n ts  lead ing  to  C M V -IP  in 7 p a t ie n ts  (fa ta l in 4) an d  a 
n o n fa ta l  g a s t ro e n te r i t i s  in 1 p a t ie n t  (T ab le  2). C M V  was e x ­
cre ted  in th e  u r ine  o f  22 o f  35 p a t ie n ts  w ith  regu lar  su rveillance  
cu ltu res  of th e  urine .
T a b l e  1. Blood products administered in the 3 months pre- and 3
months postgrafting
P re -B M T P ost-B M T
No.
patien ts T  ransfusions . T ransfusions pa tien ts
RCC° 29 6 (0—31)b 41 12 (6-30)
Random platelets 13 30 (6-108) 38 36 (6-222)
Single donor platelets 6 2 (2-10) 16 4 (1-10)
° Red-cell concentrates. 
b Median number of donor units (range).
T a b l e  2. CMV status of marrow donor and recipient in relation to
CMV infection or CMV disease
No.
p a t ien ts“
CMV
infection
CMV
disease6
C M V -IP c
Seroneg. recipient/seroneg. 
donor
28 0 0 0
Seroneg. recipient/seropos. 
donor
13 2 1 (0)d 0
Seropos. recipient/seroneg. 
donor
11 11 1 (1) 1 (1)
%
Seropos. recipient/seropos. 
donor
37 31 1 (0) 7 (4)
° Number of evaluable patients. 
b CMV-IP excluded.
c CMV-IP: cytomegalovirus interstitial pneumonia. 
d Number of fatal cases is given in parentheses.
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D espite  th e  use of b lood p ro d u c ts  from  C M V -u n se lec ted  
blood donors , on ly  2 o f  th e  41 rec ip ien ts  w ith  nega tive -C M V  
serology before B M T  developed  a n o n fa ta l ,  p r im a ry  infection . 
N one of th e  18 o th e r  se ronega tive  rec ip ien ts  w ho died too early  
for com ple te  follow-up show ed evidence of C M V  infec tion  
despite  serial a n d  carefu l m o n i to r in g  for C M V  infec tion . B o th  
p a t ie n ts  who developed  a p r im a ry  C M V  infection  received 
m arrow  from  a C M V -se ro p o s it iv e  donor. It is te m p t in g  to 
consider th e  d o n o r  m arro w  as th e  source o f  C M V  infec tion  in 
these  2 cases. T h is  is su p p o r te d  by th e  o b se rv a tio n  t h a t  ra t  
donor m arrow  can  read ily  t r a n s fe r  C M V  to  allogeneic rec ip ien ts  
(25). O th e r  s tud ies  have also observed  a re la t ion  be tw een  do n o r  
CM V serology a n d  C M V  in fec tion  a f te r  B M T  (7, 8). T h e  
abso lu te  absence  of C M V  in fec tion  in th e  28 evaluab le  se ro n eg ­
ative rec ip ien ts  who received m arro w  from  se ronega tive  d o n o rs  
su p p o r ts  conv inc ing ly  th e  h y p o th es is  t h a t  a t ra n s fu s io n  policy 
of leukocy te -poor b lood p ro d u c ts  is su ff ic ien t to  p re v e n t  p r i ­
m ary  C M V  in fec tions . O ur d a ta  are  in ag reem en t w ith  th e  
results  o f a m u l t ic e n te r  co n tro l led  tr ia l  in C M V -n eg a tiv e  n ew ­
born in fa n ts  w ith  se ronega tive  m o th e rs  t h a t  show ed t h a t  t r a n s ­
fus ion-acqu ired  C M V  in fec tion  can  be p re v e n te d  by leukocyte  
fi l tra tion  o f  u n sc re e n e d  blood p ro d u c ts  (26),  a n d  a n o n ra n d o m -  
ized s tu d y  of 59 se ronega tive  p a t ie n ts  w ith  hem ato log ic  m a lig ­
nancies t r e a te d  w ith  in ten s iv e  c h e m o th e ra p y  (27).  In  a recen t 
study (28),  3 o f  th e  36 se ronega tive  bone  m arro w  rec ip ien ts  
ransfu sed  w ith  blood p ro d u c ts  from  C M V -u n sc re e n e d  blood 
ionors  developed  C M V  infection . H ow ever, on ly  red-cell con- 
:en tra tes  were d ep le ted  of leukocy tes  in th is  s tu d y  (28).  T h e  
ibsence o f  C M V -Ig M  an tib o d ie s  p r io r  to  B M T  in p a t ie n ts  w ith  
eu k e m ia — tre a te d  a t  ou r  in s t i tu t io n  w ith  in ten s iv e  c h e m o th e r -  
ipy— excluded  a h igh inc idence  of recen t  p r im a ry  C M V  infec- 
ions. A nd  th is  was also an  in d ica t io n  o f  th e  low C M V  tra n s -  
nission ra te  from  ra n d o m  leukocy te -poo r  b lood p roduc ts .  In 
o n tra s t ,  K elsey  e t  al. (29) have fo u n d  t h a t  p a t ie n ts  receiving 
andom  blood p ro d u c ts  n o t  dep le ted  o f  leukocy tes  d u r in g  t r e a t ­
ment w ith  in ten s iv e  c h e m o th e ra p y  for leukem ia  show ed an  
icrease  of se ropos it iv i ty  for C M V  from  43% to  56%. 
T ra n s fu s io n  o f  b lood p ro d u c ts  from  se ronega tive  blood d o ­
ors reduces th e  inc idence  o f  p r im a ry  C M V  in fec tions  (8, 9), 
ut th is  ap p ro a c h  excludes a b o u t  40 -60%  of p o te n t ia l  blood 
Dnors (30).  B ow den  et al. (8) em p h as ized  th a t  it was a m ajor 
n d e r tak in g  to  p rov ide  se ronega tive  b lood p ro d u c ts  to  a popu- 
tion  of a p p ro x im a te ly  50 m a r ro w - t r a n s p la n t  rec ip ien ts .  P la te -  
t  t ra n s fu s io n s  from  se ronega tive  d o n o rs  in c o m b in a t io n  w ith  
ukocy te -poor red-cell c o n c e n tra te s  p re v e n te d  p r im a ry  C M V  
fection (31).  H ow ever, th is  w as only  a p a r t ia l  so lu tion  o f  th e  
oblem  o f th e  ava ilab il i ty  of se ronega tive  blood donors , as it 
as s tre ssed  in a re c e n t  review on b lo o d -co m p o n en t  th e ra p y  of 
>ne m arro w  t r a n s p la n t  rec ip ien ts  (32).
A dditiona l fac to rs  m ay  have c o n tr ib u te d  to  th e  p re v en tio n  
p r im ary  C M V  infec tions. G V H D  is a ssoc ia ted  w ith  a high 
:idence of C M V  in fec tions  a n d  fa ta l C M V  in te rs t i t ia l  pneu -  
rn itis  (1, 12, 33).  T h e  inc idence  of acu te  a n d  ch ron ic  G V H D  
th is  s tu d y  was low due to  th e  lym phocy te  dep le tion  by 
in te r f lo w  cen tr i fu g a t io n  (12, 16, 17). All p a t ie n ts  received 
/clovir for p re v en tio n  o f  he rp es  in fections. P ro p h y lac t ic  use 
acyclovir has  p roven  to  reduce s ign if ican tly  th e  risk of C M V  
ection  in seroposit ive  p a t ie n ts  a f te r  allogeneic bone  m arrow  
n sp la n ta t io n ,  b u t  its  p ro tec t iv e  role in se ronega tive  recipi- 
:s rem a in s  con jec tu ra l  (12).  P ass ive  im m u n iz a t io n  w ith  hy-
p e r im m u n e  globulin  is still a co n trovers ia l  issue in bone m arrow  
t r a n s p la n ta t io n  (8, 10), b u t  it was n o t  used  for p ro p h y lax is  in 
th is  study.
B one m arrow  t r a n s p la n t  rec ip ien ts  w ith  p r im a ry  C M V  in fec ­
t ion  m ay experience  overw helm ing  C M V  infection  (34),  b u t  
b o th  p a t ie n ts  w ith  p r im a ry  C M V  infec tion  in th is  s tudy  had  
easily  con tro llab le  or subclin ica l disease. T h is  m ay have been 
due to  absence  of G V H D  at th e  t im e of developing  C M V  disease 
(1, 33)  or to  th e  use o f  acyclovir to  p re v e n t  herpes  in fec tions  
(11, 12). T  cell dep le tion  has been rep o r ted  to increase  th e  
overall inc idence of fa ta l viral in fec tions  a f te r  B M T  (35).  T h is  
p h e n o m e n o n  p robab ly  depends  on th e  m e th o d  an d  degree of T  
cell dep le tion  since several o th e r  s tud ies  on T  cell dep le tion  in 
allogeneic B M T , inc lud ing  th e  ana lys is  of lym phocy te  dep le tion  
by coun te rf low  é lu tr ia t io n  in our own in s t i tu te ,  could no t 
confirm  th is  o b se rv a tio n  (36, 16).
T h is  s tu d y  show ed th a t  th e  use of leukocy te-poor blood 
p roduc ts ,  bo th  red-cell an d  p la te le t  c o n ce n tra te s ,  from  CM V - 
u nse lec ted  b lo o d -b an k  donors  (vo lun teers)  can  p re v e n t  p r im a ry  
C M V  infection  in C M V -seronega tive  B M T  rec ip ien ts  w ith  
C M V -nega tive  m arrow  donors . M ore  th a n  98% of th e  leuko ­
cytes were rem oved  from blood p ro d u c ts  e i th e r  by leukocyte  
f i l t ra t io n  or by an  ad d it io n a l  cen tr ifu g a t io n  step. T h is  ap p ro ach  
to  p re v e n t  C M V  infection  is re la tively  sim ple, inexpensive , an d  
effective, as show n in th is  study. I t  also p re v e n ts  im m u n iza t io n  
to  h u m a n  leukocyte  an tig en  a lloan tigens  a n d  sen s i t iza t io n  to 
ra n d o m  do n o r  p la te le ts  (37).  P ro p h y lac tic  h y p e r im m u n e  g lob­
ulin a d m in is t r a t io n  did not a p p e a r  necessary  to p re v e n t  p rim o- 
in fection  w ith  C M V  in th is  ca tegory  of p a t ien ts .
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